

# Luca Mazzeella

## CURRICULUM VITAE

COGNOME	MAZZARELLA
NOME	LUCA

### FORMAZIONE

---

- 2016 **Specializzazione in Oncologia Medica**  
Università degli Studi di Milano – presso l’Istituto Europeo di Oncologia
- 2010 **PhD in Scienze Cliniche - Epigenetica**  
Imperial College, University of London, UK
- 2004 **Laurea in Medicina e Chirurgia**  
Università Cattolica, Roma, 110/110 cum laude
- Esperienze extra-curricolari:*
- 2003 Visiting student, UCL MiddleSex Hospital, London UK  
2002 Visiting student, Temple University, Philadelphia PA, USA  
2002 Erasmus Student, University of Wales, Cardiff UK  
2001 Visiting student, Thomas Jefferson University, Philadelphia PA, USA
- 1998 **Maturità Classica**  
Liceo Classico G. Palmieri, Lecce, Italy, 60/60

### ESPERIENZA LAVORATIVA

---

- 2019-on **Direttore di Unità di Ricerca e Clinician Scientist**  
Istituto Europeo di Oncologia, Dipartimento di Oncologia Sperimentale e Divisione Nuovi Farmaci
- Direttore del Laboratorio di Oncologia Traslazionale
  - Principal investigator di numerosi studi in ricerca di base e traslazionale
  - Sub-investigator di numerosi studi di fase 1
  - Attività clinico-assistenziale nel reparto di Oncologia Medica
  - Responsabile dell’area di ricerca del laboratorio di Genomica Clinica
- 2016-19 **Oncologo Medico strutturato e senior post-doctoral fellow**  
Istituto Europeo di Oncologia, Dipartimento di Oncologia Sperimentale e Divisione Nuovi Farmaci
- Principal investigator di numerosi studi in ricerca di base e traslazionale
  - Sub-investigator di numerosi studi di fase 1
  - Attività clinico-assistenziale nel reparto di Oncologia Medica
- 2011-16 **Medico Specializzando e post-doctoral fellow**  
Istituto Europeo di Oncologia, Dipartimento di Oncologia Sperimentale e Divisione Nuovi Farmaci
- Attività ambulatoriale e Day Hospital e gestione pazienti in studi clinici di fase 1/2
  - Rotazione di 6 mesi (“tronco comune”) in Medicina Interna presso il Policlinico Ca’ Granda di Milano
  - Ricerca di laboratorio su metabolismo in tumori e sistema immunitario
- 2010-11 **Postdoctoral Fellow**  
Istituto Europeo di Oncologia, Dipartimento di Oncologia Sperimentale e Divisione Nuovi Farmaci
- Ricerca di laboratorio su metabolismo in tumori e sistema immunitario

2005-10 **Studente PhD e Honorary Senior House Officer**

MRC-Clinical Sciences Centre at Imperial College e Hammersmith Hospital NHS trust, London, UK

- Ricerca di laboratorio su epigenetica in ematopoiesi
- Attività clinica ambulatoriale e in day hospital in Oncologia Medica e Emato-oncologia

**GRANT**

---

2022-26 AIRC My First Grant

- Titolo: *NF1 in metastasis and selective response to HER2-targeted drugs. Towards rational treatment of metastatic breast cancer*
- Ruolo: Principal Investigator
- Budget: 499,675.00 Euro

2020-23 Ministero della Salute, Ricerca Finalizzata – Giovani Ricercatori

- Titolo: *Making sense of the obesity paradox in melanoma immunotherapy: molecular mechanisms of tumor microenvironment modulation by fatty acids*
- Ruolo: Principal Investigator
- Budget: 448,000.00 Euro

2020 Grant Regione Lombardia/Fond. Cariplo/ Fondazione Umberto Veronesi

- Titolo: *Terapia EPIgenetica per il trattamento delle infezioni da COronavirus. (EPICO)*
- Ruolo: Direttore Unita' esterna
- Budget totale: 250,000.00 Euro

2020-24 Grant europeo H2020 (SC1-BHC-10-2019): Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis.

- Titolo: *NGS diagnostics in 21st century oncology: the best, for all, at all times*
- Ruolo: Referente italiano, membro dello steering committee, coordinatore del WP2.
- Total budget 10,999,659.38 Euro

2019-22 EU ERAPerMed JTC2018 - PEVO-data project

- Titolo: *Data solutions based on a basket prospective trial with pembrolizumab and Vorinostat in patients with advanced and/or recurrent squamous cell carcinoma*
- Ruolo: coordinatore unita' esterna
- Budget dell'unità: 250,000.00 Euro

2016-19 Ministero della Salute, Ricerca Finalizzata – Giovani Ricercatori

- Titolo: *Overcoming two unmet genetic challenges in Ph-negative myeloproliferative neoplasms: application of whole genome sequencing to identify the molecular basis of triple negative patients and the genetic predisposition to familial cases.*
- Ruolo: Coordinatore unità esterna
- Budget dell'unità: 210,000.00 Euro

2015-16 AIRC TRIDEO grant,

- Titolo: *Does obesity directly favor mutation accumulation in cancer?*
- Ruolo: Principal Investigator
- Budget: 100,000.00 Euro

2014-17 Ministero della Salute, Ricerca Finalizzata – Giovani Ricercatori

- Titolo: *Obesity-associated Flt3 mutations in Acute Promyelocytic Leukemia: investigating a novel paradigm for the cancer-promoting effect of obesity*
- Ruolo: Principal Investigator
- Budget: 336,000.00 Euro

- 2014-15 EHA-Jose Carreras, Young Investigator Grant, Principal Investigator
- Titolo: *Obesity-associated Flt3 mutations in Acute Promyelocytic Leukemia: investigating a novel paradigm for the cancer-promoting effect of obesity*
  - Ruolo: Principal Investigator
  - Budget: 160,000.00 Euro
- 2012-13 Fondazione Umberto Veronesi, Young Investigator Grant
- Titolo: *Obesity-associated Flt3 mutations in Acute Promyelocytic Leukemia: investigating a novel paradigm for the cancer-promoting effect of obesity*
  - Ruolo: Principal Investigator
  - Budget: 110,000.00 Euro

## PREMI

---

- 2018 ESMO travel award, TAT conference
- 2017 ESMO travel award, colorectal cancer preceptorship
- 2017 ESMO travel award, MAP conference
- 2016 AACR-ASCO-EACR-ECCO Methods in Clinical Cancer Research (“Flims course”)
- 2015 ASH Abstract Achievement Award
- 2015 ESMO Masterclass in Oncology
- 2013 ASH Abstract Achievement Award
- 2012 EHA-ASH Translational Research Training in Hematology
- 2012 IFRc-SIgN Advanced School of Immunology Award, Osaka, Japan
- 2011 AACR Travel grant: Metabolism and Cancer, Baltimore, US
- 2010 EMBO Poster Prize Award, Immunology and Metabolism, Marseille, France
- 2008 Roche Continents Award

## ATTIVITÀ DI CONSULENZA SCIENTIFICA

---

- 2021-on Member of the Fondation ARC Scientific Board
- 2020-22 Progetto europeo “1 Million Genomes”. Referente italiano di Work Package
- 2019-on Tethis Inc. membro del Scientific Advisory Board
- 2018-on Segretario del Working Group di Genomica - Alleanza Contro il Cancro
- 2012-on Commissione selezione fellowship, Fondazione Umberto Veronesi
- 2018-on Membro, commissione ACC-Ministero per l’implementazione del GDPR negli IRCCS
- 2019 Grant reviewer, Exactis IIT Precision Oncology Canada
- 2021 Grant reviewer, Istituto Nazionale Tumori Regina Elena
- 2018 Grant reviewer, Istituto Nazionale Tumori Regina Elena

## ESPERIENZA DIDATTICA

---

### Docenza/tutoraggio

- 2021-22 CdL in Biomedical Omics, Università Statale di Milano
- Professore a contratto, MED/03, modulo “Omics in Diagnostics” (cod 987-3640)
- 2016-20 SEMM-European School of Molecular Medicine:
- Membro della commissione di ammissione alla scuola di dottorato dal 2019
  - Membro del collegio dei docenti dal 2019
  - Docente nel corso di Cancer Genetics dal 2016
  - Docente nel corso di Genomics dal 2018
- 2018 Tutor Facoltà di Medicina, Università di Milano – Bicocca
- Attività di tutoraggio in Patologia Generale
- 2006 Tutor, Imperial College London, Faculty of Medicine
- Ciclo di seminari nel corso di Molecular Medicine

## PhD supervisor

2021-on Dott. F. Vicini, Molecular Oncology, SEMM-European School of Molecular Medicine  
2021-on Dott. E. Messuti, Molecular Oncology, SEMM-European School of Molecular Medicine  
2020-on Dott. E. Bonetti, Computational Biology, SEMM-European School of Molecular Medicine  
2019-on Dott. G. Vozza, Computational Biology, SEMM-European School of Molecular Medicine  
2019-on Dott. D. Trastulli, Molecular Oncology, SEMM-European School of Molecular Medicine  
2018-on Dott. B. A. Duso, Molecular Oncology, SEMM-European School of Molecular Medicine  
2014-18 Dott P. Falvo, Molecular Oncology, SEMM-European School of Molecular Medicine

#### **PhD thesis examiner**

2020 Dott. A. Darwich, Molecular Oncology, SEMM-European School of Molecular Medicine  
2018 Dott. I. Galasso, Foundations of Life Science (FOLSATEC), SEMM

#### **Relatore/correlatore di tesi di laurea o master**

2020 R. Caiafa, CdL in Farmacologia, Università Statale di Milano  
2020 I. Coco, CdL in Farmacologia, Università Statale di Milano  
2019 G. Camponogara, CdL in Medicina, Università Statale di Milano  
2018 E. Benevento, CdL in Economia, Università di Pavia  
2016 C. Ingoglia, CdL in Informatica, Università di Milano-Bicocca  
2013 A. Hefnawy, Master in Biology, University of Nijmegen, Netherlands  
2012 G. Melloni, CdL in Statistica, Università di Milano-Bicocca  
2011 S. Caputo, CdL in Biotecnologie, Università di Bari

#### **Seminari**

2020 International Course in Drug Development in Oncology, Institut Curie, Paris

#### **Altre attività didattiche**

2016 Seminario nel corso di arti performative, Accademia di Belle Arti di Brescia  
2014-16 Seminari in istituti superiori nei progetti "AIRC per la scuola"  
2010 Seminario presso l'istituto ITIS E. Medi, Galatone (LE)

#### **RICERCA CLINICA**

---

Good Clinical Practice (GCP) certificate dal 6/9/2016

#### **Co-Principal investigator** nei seguenti trial clinici:

- *Evaluating the feasibility of NGS-based germline and somatic genetic testing in triple-negative breast cancer. The PERSONA-breast trial*
- *Evaluating the feasibility of NGS-based germline and somatic genetic testing in ovarian carcinoma. The PERSONA-ovary trial*
- *Validation of the Alliance Against Cancer lung panel in patients with Non Small Cell Lung Cancer*
- *Eudract 2017-003216-39 Clinical utility of a next generation sequencing-based "oncochip" for therapeutic decision in metastatic breast cancer: the SHARP trial*
- *GerSom. Studio di fattibilità per la diagnosi genomica congiunta di rischio genetico e di sensibilità ai nuovi farmaci nelle neoplasie del seno, ovaio e colon*

#### **Responsabile di unità** per studi traslazionali ancillari nei seguenti trial:

- *Phase II basket trial evaluating the efficacy of a combination of pembrolizumab and vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma. Eudract 2019-003839-33*
- *Primary Ipilimumab and Nivolumab combo-immunotherapy followed by adjuvant Nivolumab in locally advanced or limited metastatic melanoma. Eudract 2018-002172-40*

#### **Sub investigator** in numerosi trial clinici inclusi i seguenti:

- ClinicalTrials.gov NCT02671435 (NKG2A agonist Monalizumab + Durvalumab)
- Eudract 2015-002354-12 (anti Tim3 MBG453 + Spartalizumab)
- Eudract 2015-002505-11 (Anti-GITR BMS-986156 + Nivolumab)

- Eudract 2016-000210-29 (anti-MCSF MCS110 + Spartalizumab)
- Eudract 2016-000320-26 (Anti PD1 Dostarlimab)
- Eudract 2014-002605-38 (Anti LAG3 Relatlimab)
- Eudract 2015-004914-79 (anti IDO1 BMS-986205 + Nivolumab)
- ClinicalTrials.gov NCT03301896 (TLR7 agonist LHC165 + Spartalizumab)
- Eudract 2016-002807-24 (FRACTION Gastric master protocol with multiple immunotherapeutics)
- Eudract 2015-002251-97 (IL2V-FAP antibody conjugate RO6874281 with Trastuzumab and Cetuximab)
- ClinicalTrials.gov NCT02264418 (FGFR inhibitor ODM203)
- Eudract 2016-004390-41 (RET Inhibitor BLU667)
- Eudract 2015-005243-13 (LSD1 inhibitor CC90011)
- Eudract 2016-004986-18 (Trastuzumab Duruxtecan)
- Eudract NCT03386513 (IMGN632 anticorpo coniugato anti-CD123+alchilante in neoplasia ematologiche)

### ATTIVITÀ SCIENTIFICA

---

- Abilitazione Scientifica Nazionale in settore MED 06/D3 dal 31/05/2021 al 31/05/2030
- Autore di 51 lavori peer-reviewed in extenso di cui 24 come primo autore e/o corresponding, 1 capitolo di libro, 18 proceedings di conferenze pubblicati.
- H index 17 (Scopus), 17 (Web of Science), 21 (Google Scholar), ORCID ID 0000-0002-4043-3279
- Invitato o selezionato per presentazioni orali in >30 congressi nazionali o internazionali, incluse presentazioni orali a 2 congressi ASH, 2 ESMO Immuno-Oncology, ESMO MAP, EMBO e altri.
- Membro del comitato scientifico dei congressi ESMO Immuno-Oncology 2020 e 2021, Best of ASCO Italy 2020 e ACC 2017.
- Abstract Reviewer per SITC 2021
- Co-autore di un pacchetto software (Precision Trial Drawer) depositato presso repository Bioconductor

### PUBBLICAZIONI PEER-REVIEWED

---

1. Fancello L... et al Mazzarella L\*, *TMBleR, a bioinformatic tool to optimize TMB estimation and predictive power* **Bioinformatics**, 2021 in press
2. Mazzarella L et al, *Advances in immune therapies in haematological malignancies*, **J Intern Med** 2021, online ahead of print
3. Corso F et al *The Challenge of Choosing the Best Classification Method in Radiomic Analyses: Recommendations and Applications to Lung Cancer CT Images* **Cancers (Basel)**, 2021 Jun 21;13(12):3088
4. Lazzeroni M et al *A meta-analysis of obesity and risk of colorectal cancer in patients with Lynch Syndrome: the impact of sex and genetics* **Nutrients** 13 (5), 1736
5. De Guillebon E et al, *Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial* **ESMO Open** 2021 Apr 14;6(3):100106
6. Tarantino P et al, *The evolving paradigm of biomarker actionability: histology-agnosticism as a spectrum, rather than a binary quality*, **Cancer Treatment Reviews**, 2021 Mar;94:102169
7. Favalli V, ... Mazzarella L\*, *Machine learning-based reclassification of germline variants of unknown significance: the RENOVO algorithm*, **Am J Hum Gen**, 2021 Apr 1;108(4):682-695
8. Krol et al, *Detection of Clustered Circulating Tumor Cells in Early Breast Cancer*, **Br J Cancer**, 2021 Mar 24
9. Esposito A et al, *Body mass index, adiposity and tumor infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: a multi-parametric analysis*, **Eur J Cancer** 2021 Mar;145:197-209

10. Gregorc V, Mazzarella L\* et al *Prospective validation of the Italian Alliance Against Cancer lung panel in patients with advanced Non Small Cell Lung Cancer*. **Clinical Lung Cancer**, 2021 Feb 25:S1525-7304(20)30350-8
11. Caini et al, *Circulating tumour DNA and melanoma survival: a systematic literature review and meta-analysis*, **Crit Rev Onc Hem**, 2020 Nov 27;157:103187
12. Mazzarella L\* et al *Evidence for IL17 involvement in severe immune-related neuroendocrine toxicity*, **Eur J Cancer**, 2020 Nov 10;141:218-224.
13. Tini G, ... Mazzarella L\* *Semantic and geographical analysis of Covid-19 trials reveals a fragmented clinical research landscape likely to impair informativeness*. **Front in Med** 2020 Jun 29;7:367
14. Caini et al *Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications*. **Eurosurveillance** 2020 Jun;25(23):2000980
15. Duso B et al *Pharmacological Management of Male Breast Cancer* **Expert Opin Pharmacother** 2020 Jun 4;1-12
16. Mazzarella L et al *Master Protocols in Immuno-Oncology: Do Novel Drugs Deserve Novel Designs?* **J Immunother Cancer** 2020 Mar;8(1):e000475
17. Mazzarella L\* et al *Obesity Is A Risk Factor For Acute Promyelocytic Leukemia: Evidence From Population And Cross-Sectional Studies Studies And Correlation With Flt3 Mutations And Polyunsaturated Fatty Acid Metabolism*, **Haematologica**, 2020 Jun;105(6):1559-1566
18. Fancello L, ...and Mazzarella L\*, *Tumor mutational burden quantification from targeted gene panels: major advancements and challenges* **J Immunother Canc**, 2019 7:183
19. Mazzarella L et al, *The evolving landscape of "Next Generation" Immune-checkpoint inhibitors. A review*, **Eur J Cancer**, 2019 Jun 20;117:14-31
20. Elgendy M et al, *Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating PP2A-GSK3 $\beta$ -MCL-1 axis* **Cancer Cell**, 2019 May 13, 35, 798-815
21. Pallavi R, Mazzarella L\* and Pelicci PG *Advances in precision epigenetic treatment for Acute Promyelocytic Leukemia* **Exp Rev Prec Med Drug Dev**, in press
22. Duso BA et al, *An Analysis of Available Biomarker Data For Targeting Cyclin-Dependent Kinases 4 and 6 (CDK4/6) in Breast Cancer* **Exp Rev Prec Med Drug Dev**, in press
23. Santoro A et al, *P53-loss in breast cancer leads to Myc activation, increased cell plasticity and expression of a mitotic signature with unique prognostic value* **Cell Rep**, 2019 Jan 15;26(3):624-638
24. Belli C et al, *Liver Toxicity in the Era of Immune Checkpoint Inhibitors* **Crit Rev Onc Hem** 2018:132, 125–129
25. Melloni GE...and Mazzarella L\* *Precision Trial Drawer (PTD), a computational tool to assist planning of genomics-driven trials in oncology* **JCO Prec Onc** 2018:2, 1-16
26. Mazzarella L, Guida A, Curigliano G, *Cetuximab for treating non-small cell lung cancer* **Exp Op on Biol Ther** 2018 Apr;18(4):483-493
27. Mazzarella L\*, *Are we ready for routine precision medicine? Highlights from the Milan Summit on Precision Medicine, Milan, Italy, 8–9 February 2018* **Ecancer** 2018 Mar 5;12:817
28. Mazzarella L and Curigliano G *A new approach to assess drug sensitivity in cells for novel drug discovery in oncology* **Exp Op on Invest Drugs** 2018 Apr;13(4):339-346
29. Duso BA et al *Clinical efficacy of ribociclib as a first-line therapy for HR- positive, advanced breast cancer* **Exp Op On Pharmacother** 2018 Feb;19(3):299-305
30. TrabANELLI S, Chevalier M, Martinez Usatorre A, et al *Tumor-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis*, **Nature Comm**, 2017 8(1):593
31. Trapani D, Criscitiello C, Esposito A, Mazzarella L, et al *Entinostat for the treatment of breast cancer* **Exp Op on Invest Drugs**, 2017 Aug;26(8):965-971
32. Melloni G, Mazzarella L, Bernard L, Bodini M, Russo A, et al, *A knowledge-based framework for the discovery of cancer predisposing variants using large-scale sequencing breast cancer data*, **Breast Can Res Treat** 2017 May 31;19(1):63
33. Mazzarella L, *Highlights from the 58th meeting of the American Society of Haematology*. **Ecancer** 2017 Mar 9;11:725

34. Rossi A, Ferrari KJ, Piunti A, et al *Maintenance of Leukemic Cell Identity by the Activity of the Polycomb Complex PRC1 in Mice* **Science Adv**, 2016 Oct 7;2(10)
35. Mazzarella L\*, *Orlando Magic: report from the 57th meeting of the American Society of Haematology*, **Ecancer** 2016 Jan 14;10:612
36. Mazzarella L\*, *Why does obesity promote cancer? Epidemiology, biology ad open questions* **Ecancer**, 2015 9;554 (as part of special issue on Metabolism and Cancer, curated by Mazzarella L) \*corresponding author
37. Mazzarella L\*, Riva L, Luzi L, Ronchini C, Pelicci PG *The genomic and epigenomic landscape of AML* **Sem Hematol** 2014 Oct;51(4):259-72 \*corresponding author
38. Mazzarella L\*, *Rise of the mutants: report from the 19th conference of the European Haematology Association*, **Ecancer** 2014 Aug 18;8:453
39. Melloni GEM, Ogier A, de Pretis A, Mazzarella L et al *DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes* **Genome Medicine** 2014 Jun 10;6(6):44
40. Mazzarella L\* *Tales from the Jazz ASH: highlights from the 2013 American Society of Hematology Meeting*, **Ecancer**, 2014 Jan 24;8:390
41. Mazzarella L\*, Disalvatore D, Bagnardi V, et al *Obesity increases the incidence of distant metastases in oestrogen receptor-negative HER2+ breast cancer patients*, **Eur J Canc** 2013 Nov;49(17):3588-97
42. Ferri N, Cazzaniga S, Mazzarella L, et al *Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in Pt<sup>II</sup> complexes on human carcinoma cell lines: a comparative study with cisplatin* **Bioorg Med Chem** 2013 Apr 15;21(8):2379-86
43. Ribeiro JT, Macedo LT, Curigliano G, et al *Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: Back to the future?* **Ann Oncol** 2012, Mar;23(3):547-55
44. Breccia M<sup>#</sup>, Mazzarella L<sup>#</sup>, et al *Increased body mass index correlates with higher risk of differentiation syndrome and disease relapse in patients with newly diagnosed acute promyelocytic leukemia treated with AIDA protocols*. **Blood** 2012, Jan 5;119(1):49-54 <sup>#</sup>equal contribution
45. Mazzarella L, et al. *ES cell-derived hemangioblasts remain epigenetically plastic and require PRC1 to prevent neural gene expression*. **Blood**. 2011 Jan 6;117(1):83-7
46. Liber D, Domaschensz R, Holmqvist PH, Mazzarella L et al *Epigenetic priming of a pre-B cell-specific enhancer through binding of Sox2 and Foxd3 at the ESC stage*. **Cell Stem Cell**. 2010 Jul 2;7(1):114-26.
47. Auner HW, Mazzarella L, et al. *High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma*. **Bone Marrow Transplant**. 2010 Jun 21, 46(3), 364-367
48. Landeira D, Sauer S, Poot R, Dvorkina M, Mazzarella L, et al *Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA Polymerase II to developmental regulators*. **Nat Cell Biol**. 2010 Jun;12(6):618-24
49. Bruno L, Mazzarella L, et al. *Runx proteins regulate Foxp3 expression*. **J Exp Med**. 2009 Oct 26;206(11):2329-37.
50. Hoogenkamp M, Lichtinger M, Krysinska H et al. *Early chromatin unfolding by RUNX1: a molecular explanation for differential requirements during specification versus maintenance of the hematopoietic gene expression program*. **Blood**. 2009 Jul 9;114(2):299- 309.
51. Cetta F, Mazzarella L, et al: *Genetic alterations in hepatoblastoma and hepatocellular carcinoma associated with familial adenomatous polyposis* **Med Pediatr Oncol**. 2003 Nov; 41(5):496-7

\*corresponding author

---

#### CAPITOLI IN LIBRI

*Fundamental Pathways in Breast Cancer 4: Signaling to Chromatin* in "Breast Cancer: Innovations in Research and Management", Springer, 2017. Autore del capitolo e co-editor di sezione

---

#### SOFTWARE

Precision Trial Drawer (PTD), depositato in Bioconductor

<https://bioconductor.org/packages/devel/bioc/html/PrecisionTrialDrawer.html>

## PARTECIPAZIONI A CONGRESSI – COMITATO SCIENTIFICO

---

2021	ESMO Immuno-Oncology conference: Scientific Committee
2020	ESMO Immuno-Oncology conference: Scientific Committee and Oral Discussant
2020	Best of ASCO Italy – Co-Chair of Early Drug Development track
2017, 20	Alleanza Contro il Cancro national meeting

## PARTECIPAZIONI A CONGRESSI – PRESENTAZIONI ORALI

---

2021	AIOM
2021	ESMO Immuno-Oncology
2021	Best of ASCO 2021
2021	Precision Medicine in Hematology, Nobel Forum, Karolinska Institut Stockholm
2020	ESMO Immuno-Oncology
2020	Best of ASCO 2020
2020	Nuove frontiere del Next Generation Sequencing, Verona
2019	X Congresso Nazionale IG-IBD (Societa' Malattie Infiammatorie Intestinali)
2019	Molecular Tumor Boards: governare il presente per costruire il futuro
2019	Alleanza Contro il Cancro National meeting
2019	AIOM Cagliari
2019	"Medicina di Precisione" Palermo
2018	Cancer Immunotherapy Day, Madrid
2018	BITS - Italian Bioinformatics Society annual meeting
2018	Alleanza Contro il Cancro national meeting
2017	ESMO MAP - Molecular Analysis for Personalized Therapy
2017	"Conquer Breast Cancer" Workshop
2017	Alleanza Contro il Cancro National meeting
2016	Italian Ministry of Health meeting on "Big Data in Medicine"
2016	EU-Life Annual Meeting, CeMM Vienna
2015	American Society of Hematology Meeting, Orlando, FA, USA
2015	Associazione Biologia Cellulare e del Differenziamento, annual meeting
2015	American Society for Investigative Pathology Boston, MA USA
2014	EMBO meeting on Frontiers in Metabolism, Heidelberg
2014	Roche Breast Cancer Masterclass
2013	American Society of Hematology Meeting, New Orleans, LA USA
2013	Roche Breast Cancer Masterclass
2013	6th symposium on Acute Promyelocytic Leukemia, Rome
2013	Milan Breast Conference ( <i>session co-chair</i> )
2011	EMBO meeting on Immunology and Metabolism, Marseille, France

## PARTECIPAZIONI A CONGRESSI – ABSTRACT PUBBLICATI

---

1. Mazzarella et al *Involvement of IL17 in a case of fatal neuroendocrine toxicity associated with dual immune checkpoint blockade*, SITC 2019, **J Immunother Canc** 2019, vol 7
2. Fancello et al *TMBler: a bioinformatic tool for measuring and optimizing Tumor Mutational Burden quantification from targeted sequencing panels*, SITC 2019, **J Immunother Canc** 2019, vol 7
3. Gregorc et al *Expanding Access to Large-Scale Genomic Mutational Analyses for Patients with Advanced NSCLC in Italy*, IASCLC 2019, **J Thor Onc** (2019), 14 (10): S381
4. Molineris et al *The ACC melanoma pilot project: "Real-world" evaluation of an NGS platform for molecular characterization of melanoma in Italy*, ASCO 2019, **J Clin Onc** 37, no. 15\_suppl
5. Duso et al *Secondary mechanisms of anti-HER2 resistance in breast cancer: NF1 as an actionable target* ESMO 2019, **Ann Oncol** (2018) 30 (s3): mdz095. 017
6. Ferraro et al *Safety of immunotherapy in elderly patients: A retrospective analysis of a phase I unit* **Ann Oncol** (2018) 29 (s8): 438
7. Diamond et al *Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A)*, ESMO 2018 **Ann Oncol** (2018) 29 (s8): 425



8. Mazzearella et al *Obesity favours leukemogenesis through enhanced preleukemic stem cell self renewal via polyunsaturated fatty acid-dependent ER stress relief* AACR 2018, **Cancer Res** (2018) 78 (s13); 450
9. Mazzearella et al *Precision trial designer-web: A web-based app to assist in the design of genomics-driven trials*, ESMO MAP **Ann Oncol** (2018), vol 29 p26
10. TrabANELLI et al *Tumor-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis in acute promyelocytic leukemia* **J Immunother Canc** 2017, vol 5
11. Mazzearella et al *Precision Trial Designer: A computational tool to assist in the design of genomics-driven trials in oncology*, **Ann Oncol** (2017) v28, vii3-vii4
12. Mazzearella et al *Genome-wide identification of actionable copy number alterations from targeted sequencing panels with Excavator2*, ESMO MAP 2017, **Ann Oncol** (2017) v28, s7 vii2-vii3
13. Mazzearella et al, *Obesity As a Risk Factor for Acute Promyelocytic Leukemia. Results from Population and Case-Control Studies Across Western Countries and Correlation with Gene Expression in the TCGA*, ASH 2015, **Blood** (2016) 128 (22): 448.
14. Mazzearella et al *Inhibition of the Histone Demethylase LSD1 Combined with Caloric Restriction or IGF1/Insulin Inhibition Leads to Durable Responses in a Preclinical Model of Acute Myeloid Leukemia*, ASH 2014, **Blood** (2015), 126 (23); 459
15. Mazzearella et al *Modelling the influence of diet on APL identifies Insulin-Growth Factor 1 as a central mediator and provides a mechanistic rationale for therapeutic weight loss*, ASH 2012, **Blood** (2013) 122 (21), 833-833
16. Durfort et al, *Insulin/IGF1 Pathway Inhibition in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia*, ASH 2012, **Blood** (2012) 120 (21), 1347-1347
17. Auner et al *High rate of stem cell mobilization failure after thalidomide and cyclophosphamide induction therapy for myeloma*, **Bone Marrow Transplantation** (2010), 45 S21
18. Auner et al, *The Combination of Cyclophosphamide and Thalidomide During Induction Therapy for Multiple Myeloma Results in a High Rate of Stem Cell Mobilization Failure*, ASH 2009, **Blood** (2009) 114 (22): 2147

---

#### ATTIVITA' EDITORIALE

**Editorial board member:** Journal for Immunotherapy of Cancer, Frontiers in Oncology, Frontiers in Genetics, Public Health Genomics, E Cancer, Biomedicine

**Reviewer** per Plos Medicine, Nature Computational Science, Oncogene, European Journal of Cancer, Journal for Immunotherapy of Cancer, Haematologica, British Journal of Cancer, Blood Cancer Discovery, Journal of Molecular Diagnostics, Nature Scientific Reports, European Journal of Human Genetics, Cancer Treatment Reviews, Annals of Surgical Oncology, Frontiers in Oncology, Frontiers in Genetics, Frontiers in Immunology, ACS Applied Biomaterials, The Breast, Plos One, Lung Cancer, BMC cancer, Journal of Experimental & Clinical Cancer Research, E Cancer, Clinical and Translational Medicine, Leukemia Research, Heliyon

**Abstract Reviewer** per SITC 2021, ESMO IO 2020 e 2021

---

#### MEMBERSHIP IN SOCIETA' SCIENTIFICHE

SITC - Society for Immunotherapy of Cancer dal 2019

AACR - American Association for Cancer Research dal 2011

ESMO – European Society for Medical Oncology dal 2017

EHA – European Haematology Association dal 2012

---

#### ALTRO

**Lingue:** Italian (native), English (fluent), French (fluent), Spanish (Advanced)

**Computer literacy:** Proficient in R programming, Adobe and Office suites

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D. Lgs. 196/2003 e all'art. 13 GDPR (Regolamento UE 2016/679) ai soli fini della ricerca e selezione del personale.

Data

7/12/2021

Luogo

Milano

A handwritten signature in black ink, appearing to read "Adamo", written in a cursive style.